Can Toll-Like Receptor (TLR) 2 be considered as a new target for immunotherapy against hepatitis B infection?

Human Immunology

Volumn 75, Issue 6, 2014, Pages 549-554

  Bagheri, Vahid ^a   Askari, Azam ^a   Arababadi, Mohammad Kazemi ^a   Kennedy, Derek ^b  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HETERODIMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; MYD88 PROTEIN, HUMAN; TLR2 PROTEIN, HUMAN; TLR6 PROTEIN, HUMAN;

HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; LIVER NEOPLASMS; PROTEIN MULTIMERIZATION; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6;

EID: 84900469581     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.02.018     Document Type: Review

References (65)

1. Assar S., Arababadi M.K., Ahmadabadi B.N., Salehi M., Kennedy D. Occult hepatitis B virus (HBV) infection: a global challenge for medicine. Clin Lab 2012, 58:1225.
2. Ayoobi F., Hassanshahi G., Zainodini N., Khorramdelazad H., Arababadi M.K., Kennedy D. Reduced expression of TRIF in chronic HBV infected Iranian patients. Clin Res Hepatol Gastroenterol 2013, 37:491.
3. Khorramdelazad H., Hassanshahi G., Nasiri Ahmadabadi B., Kazemi Arababadi M. High serum levels of TGF-beta in Iranians with chronic HBV infection. Hepat Mon 2012, 12:e7581.
4. Chan H.L., Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol 2011, 26(Suppl. 1):131.
5. Arababadi M.K., Pourfathollah A.A., Jafarzadeh A., Hassanshahi G., Rezvani M.E. Association of exon 9 but not intron 8 VDR polymorphisms with occult HBV infection in south-eastern Iranian patients. J Gastroenterol Hepatol 2009, 25:90.
6. Mendy M.E., Welzel T., Lesi O.A., Hainaut P., Hall A.J., Kuniholm M.H., et al. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia. West Africa. J Viral Hepat 2009, 27:27.
7. Michielsen P., Ho E. Viral hepatitis B and hepatocellular carcinoma. Acta Gastroenterol Belg 2011, 74:4.
8. Ahmadabadi B.N., Hassanshahi G., Arababadi M.K., Leanza C., Kennedy D. The IL-10 promoter polymorphism at position-592 is correlated with susceptibility to occult HBV infection. Inflammation 2012, 35:818.
9. Khvalevsky E., Rivkin L., Rachmilewitz J., Galun E., Giladi H. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 2007, 100:1301.
10. Momeni M., Zainodini N., Bidaki R., Hassanshahi G., Daneshvar H., Khaleghinia M., et al. Decreased expression of toll like receptor signaling molecules in chronic HBV infected patients. Hum Immunol 2014, 75:15.
11. Nguyen-Pham T.N., Lim M.S., Nguyen T.A., Lee Y.K., Jin C.J., Lee H.J., et al. Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists. Cell Mol Immunol 2011, 8:341.
12. Hirayama T., Tamaki Y., Takakubo Y., Iwazaki K., Sasaki K., Ogino T., et al. Toll-like receptors and their adaptors are regulated in macrophages after phagocytosis of lipopolysaccharide-coated titanium particles. J Orthop Res 2011, 29:984.
13. Bae Y.S., Lee J.H., Choi S.H., Kim S., Almazan F., Witztum J.L., et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res 2009, 104:210.
14. Imani Fooladi A.A., Mousavi S.F., Seghatoleslami S., Yazdani S., Nourani M.R. Toll-like receptors: role of inflammation and commensal bacteria. Inflamm Allergy Drug Targets 2011, 10:198.
15. Rusz A., Pilatz A., Wagenlehner F., Linn T., Diemer T., Schuppe H., et al. Influence of urogenital infections and inflammation on semen quality and male fertility. World J Urol 2012, 30:23.
16. Oliveira-Nascimento L., Massari P., Wetzler L.M. The Role of TLR2 in Infection and Immunity. Front Immunol 2012, 3:79.
17. Arababadi M.K., Ahmadabadi B.N., Kennedy D. Current information on the immunological status of occult hepatitis B infection. Transfusion 2012, 52:1819.
18. Khorramdelazad H., Hassanshahi G., Ahmadabadi B.N., Arababadi M.K. High serum levels of TGF-β in Iranians with chronic HBV infection. Hepat mon 2012, 12:e7581.
19. Hassanshahi G., Arababadi M.K., Khoramdelazad H., Yaghini N., Zarandi E.R. Assessment of CXCL12 (SDF-1alpha) polymorphisms and its serum level in posttransfusion occult HBV-infected patients in Southeastern Iran. Arch Med Res 2010, 41:338.
20. Tujios S.R., Lee W.M. Update in the management of chronic hepatitis B. Curr Opin Gastroenterol 2013, 29:250.
21. Scaglione S.J., Lok A.S. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012, 142:1360.
22. Papatheodoridis G.V. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?. Liver Int 2013, 33(Suppl. 1):151.
23. Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998, 95:588.
24. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798.
25. Preiss S., Thompson A., Chen X., Rodgers S., Markovska V., Desmond P., et al. Characterization of the innate immune signalling pathways in hepatocyte cell lines. J Viral Hepat 2008, 15:888.
26. Flo T.H., Halaas O., Torp S., Ryan L., Lien E., Dybdahl B., et al. Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol 2001, 69:474.
27. Kohanawa M., Zhao S., Ozaki M., Haga S., Nan G., Kuge Y., et al. Contribution of toll-like receptor 2 to the innate response against staphylococcus aureus infection in mice. PLoS One 2013, 8:e74287.
28. Szomolanyi-Tsuda E., Liang X., Welsh R.M., Kurt-Jones E.A., Finberg R.W. Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. J Virol 2006, 80:4286.
29. Dolganiuc A., Oak S., Kodys K., Golenbock D.T., Finberg R.W., Kurt-Jones E., et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004, 127:1513.
30. Leoni V., Gianni T., Salvioli S., Campadelli-Fiume G. Herpes simplex virus glycoproteins gH/gL and gB bind Toll-like receptor 2, and soluble gH/gL is sufficient to activate NF-kappaB. J Virol 2012, 86:6555.
31. Cooper A., Tal G., Lider O., Shaul Y. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol 2005, 175:3165.
32. Tsolmongyn B., Koide N., Jambalganiin U., Odkhuu E., Naiki Y., Komatsu T., et al. A toll-like receptor 2 ligand, Pam3CSK4, augments interferon-gamma-induced nitric oxide production via a physical association between MyD88 and IFN-gamma receptor in vascular endothelial cells. Immunology 2013, 140:352.
33. Abe T., Fukuhara T., Wen X., Ninomiya A., Moriishi K., Maehara Y., et al. CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction with Toll-like receptor 2 and hyaluronan. J Virol 2012, 86:6159.
34. Liang B., Chen R., Wang T., Cao L., Liu Y., Yin F., et al. Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma. Clin Cancer Res 2013, 19:2905.
35. Maeda S. NF-κB, JNK, and TLR signaling pathways in hepatocarcinogenesis. Gastroenterol Res Pract 2010, 2010:367694.
36. Gerber P.A., Buhren B.A., Steinhoff M., Homey B. Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc 2011, 15:40.
37. Fuertes E., Brauer M., MacIntyre E., Bauer M., Bellander T., von Berg A., et al. Childhood allergic rhinitis, traffic-related air pollution, and variability in the GSTP1, TNF, TLR2, and TLR4 genes: results from the TAG Study. J Allergy Clin Immunol 2013, 132:342.
38. Ryu J.H., Yoo J.Y., Kim M.J., Hwang S.G., Ahn K.C., Ryu J.C., et al. Distinct TLR-mediated pathways regulate house dust mite-induced allergic disease in the upper and lower airways. J Allergy Clin Immunol 2013, 131:549.
39. Liu Y.C., Simmons D.P., Li X., Abbott D.W., Boom W.H., Harding C.V. TLR2 signaling depletes IRAK1 and inhibits induction of type I IFN by TLR7/9. J Immunol 2012, 188:1019.
40. Dolganiuc A., Chang S., Kodys K., Mandrekar P., Bakis G., Cormier M., et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol 2006, 177:6758.
41. Thompson A.J., Colledge D., Rodgers S., Wilson R., Revill P., Desmond P., et al. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther 2009, 14:797.
42. Zhang X., Ma Z., Liu H., Liu J., Meng Z., Broering R., et al. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol 2012, 57:522.
43. Khorramdelazad H., Hakimizadeh E., Hassanshahi G., Rezayati M., Sendi H., Arababadi M.K. CCR5 δ 32 mutation is not prevalent in Iranians with chronic HBV infection. J Med Virol 2013, 85:964.
44. Chen Z., Cheng Y., Xu Y., Liao J., Zhang X., Hu Y., et al. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008, 128:400.
45. Wei X.Q., Wen Z.F., Zheng F.P., Yao J.L. Changes of Toll-like receptor (TLR) 2 and TLR4 on the peripheral blood mononuclear cells in patients with chronic hepatitis B and chronic severe hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2007, 15:354.
46. Guo Y.W., Wei X.Q., Yang S.J. A close relationship between viral hepatitis B and Toll-like receptor 2. Zhonghua Gan Zang Bing Za Zhi 2007, 15:485.
47. Heiberg I.L., Winther T.N., Paludan S.R., Hogh B. Pattern recognition receptor responses in children with chronic hepatitis B virus infection. J Clin Virol 2012, 54:229.
48. Wang S., Chen Z., Hu C., Qian F., Cheng Y., Wu M., et al. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol 2013, 190:5142.
49. Lang T., Lo C., Skinner N., Locarnini S., Visvanathan K., Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 2011, 55:762.
50. Visvanathan K., Skinner N.A., Thompson A.J., Riordan S.M., Sozzi V., Edwards R., et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007, 45:102.
51. Wilson R., Warner N., Ryan K., Selleck L., Colledge D., Rodgers S., et al. The hepatitis B e antigen suppresses IL-1beta-mediated NF-kappaB activation in hepatocytes. J Viral Hepat 2011, 18:e499.
52. Shi B., Ren G., Hu Y., Wang S., Zhang Z., Yuan Z. HBsAg inhibits IFN-alpha production in plasmacytoid dendritic cells through TNF-alpha and IL-10 induction in monocytes. PLoS One 2012, 7:e44900.
53. Liu W.H., Liu J.J., Wu J., Zhang L.L., Liu F., Yin L., et al. Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One 2013, 8:e55487.
54. Vincent I.E., Zannetti C., Lucifora J., Norder H., Protzer U., Hainaut P., et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One 2011, 6:e26315.
55. Isogawa M., Robek M.D., Furuichi Y., Chisari F.V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005, 79:7269.
56. Lagowska-Lenard M., Stelmasiak Z., Bartosik-Psujek H. Influence of vitamin C on markers of oxidative stress in the earliest period of ischemic stroke. Pharmacol Rep 2010, 62:751.
57. Chatziathanasiou G.N., Nikas D.N., Katsouras C.S., Kazakos N.D., Bouba V., Vougiouklakis T., et al. Combined intravenous treatment with ascorbic acid and desferrioxamine to reduce myocardial reperfusion injury in an experimental model resembling the clinical setting of primary PCI. Hellenic J Cardiol 2012, 53:195.
58. Wang K., Liu H., He Y., Chen T., Yang Y., Niu Y., et al. Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Hum Immunol 2010, 71:950.
59. Soares J.-B., Pimentel-Nunes P., Afonso L., Rolanda C., Lopes P., Roncon-Albuquerque R., et al. Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. Innate Immun 2012, 18:700.
60. Yunwei G., Xiuqing W., Yongwei L. Expression and clinical significance of Toll-like receptor 2 (TLR2) in patient with chronic hepatitis B - a report of 63 cases. New Med 2007, 2:004.
61. Janicko M., Veselíny E., Leško D., Jarcuška P. Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients. Ann Hepatol 2013, 12:581.
62. Li Y.J., Zhu P., Liang Y., Yin W.G., Xiao J.H. Hepatitis B virus induces expression of cholesterol metabolism-related genes via TLR2 in HepG2 cells. World J Gastroenterol 2013, 19:2262.
63. Matsuzaki K., Murata M., Yoshida K., Sekimoto G., Uemura Y., Sakaida N., et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007, 46:48.
64. Tarao K., Ohkawa S., Miyagi Y., Morinaga S., Ohshige K., Yamamoto N., et al. Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis. Scand J Gastroenterol 2013, 48:729.
65. Lian J.-Q., Wang X.-Q., Zhang Y., Huang C.-X., Bai X.-F. Correlation of circulating TLR2/4 expression with CD3+/4+/8+ T cells and Treg cells in HBV-related liver cirrhosis. Viral Immunol 2009, 22:301.